### MONDAY JUNE 4, 2012

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:00pm – 7:00pm</td>
<td>Registration Open</td>
<td>Grand Ballroom Foyer</td>
</tr>
</tbody>
</table>

### TUESDAY JUNE 5, 2012

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am – 7:00pm</td>
<td>Registration Open</td>
<td>Grand Ballroom Foyer</td>
</tr>
<tr>
<td>8:00am – 5:30pm</td>
<td>GLOBAL REGULATORY PERSPECTIVES WORKSHOP – separate registration fee required</td>
<td>Grand Ballroom B</td>
</tr>
<tr>
<td>8:00am – 3:00pm</td>
<td>FLOW CYTOMETRY WORKSHOP MAIN ROOM – separate registration fee required</td>
<td>Grand Ballroom D</td>
</tr>
<tr>
<td></td>
<td>CONCURRENT SESSIONS “A”</td>
<td>Willow A</td>
</tr>
<tr>
<td></td>
<td>CONCURRENT SESSIONS “B”</td>
<td>Willow B</td>
</tr>
<tr>
<td>8:00am – 5:00pm</td>
<td>FACT Training Workshop – separate registration fee required</td>
<td>Aspen Room</td>
</tr>
<tr>
<td>5:00pm – 7:00pm</td>
<td>FACT Training Breakout Session – separate registration fee required</td>
<td>Cedar B Room</td>
</tr>
<tr>
<td>7:00pm – 7:30pm</td>
<td>Corporate Symposium Hosted by Miltenyi Biotec (Refer to Corporate Guide for details)</td>
<td>Grand Ballroom C</td>
</tr>
<tr>
<td>7:30pm – 9:30pm</td>
<td>WELCOME ADDRESS</td>
<td>Grand Ballroom AB</td>
</tr>
<tr>
<td></td>
<td>EXHIBITS OPEN AND WELCOME RECEPTION</td>
<td>Metropolitan Ballroom &amp; Foyer, Ballard Room</td>
</tr>
</tbody>
</table>

### WEDNESDAY JUNE 6, 2012

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am – 4:00pm</td>
<td>Registration Open</td>
<td>Grand Ballroom Foyer</td>
</tr>
<tr>
<td></td>
<td>Corporate Tutorial Hosted by Owl biomedical (Refer to Corporate Guide for details)</td>
<td>Grand Ballroom A</td>
</tr>
<tr>
<td>7:30am – 8:30am</td>
<td>TECHNICAL SESSION 1</td>
<td>Grand Ballroom B</td>
</tr>
<tr>
<td></td>
<td>Imaging Cell Therapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: Rao Papineni (US)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speakers:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rao Papineni (US) – Multimodal Imaging in Cell Trafficking</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ali Arbab (US) – Imaging administered stem cells by in vivo imaging modalities</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TECHNICAL SESSION 2</td>
<td>Grand Ballroom C</td>
</tr>
<tr>
<td></td>
<td>NK Expansion for Clinical Trials</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: Didier Blaise (FR)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speakers:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Didier Blaise (FR) – Role of NK cells in allogeneic SCT and perspectives</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jeffrey Miller (US) – How to educate NK cells to treat cancer</td>
<td></td>
</tr>
</tbody>
</table>
7:30am – 8:30am

STRATEGIES FOR COMMERCIALIZATION TRACK 1

Best Practices in Cell Therapy Process Development
Chair: Jon Rowley (US)
Speakers:
Jon Rowley (US) – Designing High Impact Cell Therapy Process Development Programs
Andy Campbell (US) – Media and Process Development for Cell Therapy Applications: Implications for Scale-up and Manufacturing
Aby Mathew (US) – Designing Best Practices in Cell and Tissue Biopreservation for Clinical Process Development

8:45am – 9:00am

Opening Remarks

9:00am – 10:30am

PLENARY SESSION 1 – PRESIDENTIAL PLENARY ON MESENCHYMAL STEM CELLS

Chair: Edwin Horwitz (US)
Speakers:
Darwin Prockop (US) – Medical Therapies with Adult Stem/Progenitor Cells (MSCs): A Backward Journey from Dramatic Results in Vivo to the Cellular and Molecular Explanations
Jacques Galipeau (US) – Mesenchymal Stromal Cells for personalized cell therapy. How mechanistic cell physiology studies can inform the design of clinical trials
Massimo Dominici (IT) – Revising Janus Bifrons myth for Cellular Therapies based on Mesenchymal Progenitors

10:30am – 11:00am

Coffee Break with Exhibits

11:00am – 12:15pm

ORAL ABSTRACT PRESENTATIONS 1

Cell and Gene Therapy/Immunotherapy and Dendritic Cells

Co–Chairs: Hans–Peter Kiem (US) and Catherine Bollard (US)

MGMTp140K GENE–MODIFIED CD34+ CELLS ALLOW FOR INCREASED CHEMOTHERAPY ADMINISTRATION AND EXTENDED SURVIVAL IN POOR–PROGNOSIS GIOBLASTOMA PATIENTS (ABSTRACT#1)
Speaker: Jennifer Adair (US), Young Investigator Award Recipient

A SINGLE INFUSION OF ZINC FINGER NUCLEASE (ZFN) CCR5 MODIFIED AUTOLOGOUS CD4 T–CELLS (SB–728–T) CORRELATES WITH INCREASES IN CD4 COUNTS AND EFFECTS ON VIRAL LOAD (VL) IN AVIREMIC HIV–INFECTED SUBJECTS (ABSTRACT #2)
Speaker: Bruce Levine (US)

CATS1 STUDY: IMMUNOMONITORING AND CLINICAL RESULTS OF ANTIGEN–SPECIFIC T REGULATORY (TREG) CELL THERAPY FOR CROHN’S DISEASE (CD) (ABSTRACT #3)
Speaker: Nathalie Clerget–Chossat (FR)

COMBINATION IMMUNOTHERAPY AFTER ASCT FOR ADVANCED MYELOMA WITH MAGE–A3/POLY–ICLC IMMUNIZATION FOLLOWED BY TRANSFER OF VACCINE–PRIMED ACTIVATED AUTOLOGOUS T CELLS (ABSTRACT #4)
Speaker: Nicole Aqui (US)

EFFECTIVE PROPHYLAXIS OF CMV DISEASE IN RECIPIENTS OF ALLOGENEIC HAEMOPOIETIC STEM CELL TRANSPLANTS USING ADOPTIVE T CELL TRANSFER – LONG TERM FOLLOW-UP OF 50 PATIENTS (ABSTRACT #5)
Speaker: Emily Blyth (AU)
### ORAL ABSTRACT PRESENTATIONS 2
**Translational Process Development**

**Grand Ballroom B**

**Chair:** Jon Rowley (US)

**PROCESS SCALE-UP AND TRANSITION FROM AUTOLOGOUS TO ALLOGENEIC MANUFACTURING OF CARDIOSPHERE-DERIVED STEM CELLS (ABSTRACT #6)**  
*Speaker:* Michelle Kreke (US), Young Investigator Award Recipient

**THE CRYO-IMAGING SOUTION TO “WHERE DID MY CELLS GO” (ABSTRACT #7)**  
*Speaker:* David Wilson (US)

**NAVIGATING THE FIRST-IN-HUMAN IMPLANTABLE POLYMER-DERIVED TUMOR VACCINES INTO A CLINICAL TRIAL (ABSTRACT #8)**  
*Speaker:* Heather Daley (US), Tech Travel Award Recipient

**DEVELOPMENT OF AN ANGIGENIC POTENCY ASSAY FOR CLINICAL GRADE STEM CELL PRODUCTION (ABSTRACT #9)**  
*Speaker:* Anthony Ting (US)

**DEVELOPING LARGE SCALE CELL MANUFACTURING PROCESSES: THE IMPACT ON CELL QUALITY ATTRIBUTES AND COST OF GOODS (ABSTRACT #10)**  
*Speaker:* Hemanthram Varadaraju (US)

### ORAL ABSTRACT PRESENTATIONS 3
**Cardiovascular Repair and Regeneration/Nervous System Repair**

**Grand Ballroom C**

**Co-Chairs:** Warren Sherman (US) and Josef Priller (DE)

**A PHASE I/II STUDY ASSESSING THE SAFETY AND EFFICACY OF INTRAVENOUS EX VIVO CULTURED ADULT ALLOGENEIC MESENCHYMAL STEM CELLS IN PATIENTS WITH ST ELEVATED ACUTE MYOCARDIAL INFARCTION (STEMI) (ABSTRACT #12)**  
*Speaker:* Pawan Gupta (IN)

**IRES-BASED LENTIVIRUS CO-EXPRESSING TGFβ1 AND FGF2 IMPROVES CELL SURVIVAL AND ANGIOGENESIS IN BONE MARROW DERIVED-MESENCHYMAL STEM CELLS (ABSTRACT #13)**  
*Speaker:* Manuela Mura (IT)

**A NEW ROLE FOR MENINGES AS A NICHE FOR STEM/PRECURSOR CELLS WITH NEURAL DIFFERENTIATION POTENTIAL DURING DEVELOPMENT UP TO ADULTHOOD (ABSTRACT #14)**  
*Speaker:* Mauro Krampera (IT)

**SAFETY AND EFFICACY OF INTRACORONARY INFUSION OF ALLOGENEIC CARDIOSPHERE-DERIVED STEM CELLS IN A PIG MODEL OF MYOCARDIAL INFARCTION (ABSTRACT #11)**  
*Speaker:* Michelle Kreke (US)

**COMPARISON OF HUMAN SCHWANN CELL PROLIFERATION RATES IN CULTURE FROM ORGAN DONOR AND CADAVERIC NERVES (ABSTRACT #15)**  
*Speaker:* James Guest (US)

### STRATEGIES FOR COMMERCIALIZATION TRACK 2
**Biologics in Personalized Medicine– What are the Development Options beyond Phase 2?**

**Grand Ballroom D**

**Co-Chairs:** Shirley Bartido (US) and David DiGiusto (US)

**Speakers:**  
Renier Brentjens (US) – Clinical translation of an adoptive therapeutic approach to Cancer: Obstacles from the perspective of an academic investigator  
Martin Schroeder (US) – Attracting Partners to Help Commercialize Cell Therapy Products  
Michael Zdanowski (US) – HEMACORD®: The First FDA Approved Allogeneic (Cord Blood Derived) Stem Cell Product A Case Study: From Research to IND to BLA

**Panelists:**  
For GE: Jiwen Zhang (US) and Firman Ghouze (US)  
For CellGenix: Felicia Rosenthal (DE)  
For Lonza: Kim Warren (US)

1:45pm – 3:00pm  
**Lunch with Exhibits**

**Metropolitan Ballroom & Foyer, Ballard Room**
12:30pm – 1:30pm
Corporate Tutorial Hosted by BioLife Solutions (Refer to Corporate Guide for details) Grand Ballroom A
Corporate Tutorial Hosted by Title21 Software (Refer to Corporate Guide for details) Grand Ballroom B
Corporate Tutorial Hosted by EMD Millipore (Refer to Corporate Guide for details) Grand Ballroom C
Technologists Networking Session Chair: Lizette Caballero (US)
OPEN TO ALL ATTENDEES Willow Room

1:45pm – 3:15pm
PLENARY SESSION 2 – CARDIOVASCULAR CELL THERAPY Grand Ballroom ABC
Chair: Michael Laflamme (US)
Speakers:
Rachel Smith (US) – Autologous and Allogeneic Cardiosphere–Derived Cells for Heart Regeneration
April Stempjen–Otero (US) – Understanding Mechanisms of Cell Based Therapy in the Human Heart
Wolfram Zimmermann (DE) – Therapeutic Heart Muscle from Oocytes
Michael Laflamme (US) – Electromechanical Integration and Arrhythmogenic Risk of Human Embryonic Stem Cell–Derived Cardiomyocyte Transplantation
CME credit hours: 1

TECHNICAL APPLICATIONS TRACK 2 Willow Room
Roundtable Debate: Pros and Cons in the Cellular Therapy Field
Topic #1: Should closed systems and/or classified facilities be required for processing all cell therapy products?
Topic #2: Should donors of HPC or other cell therapy products be financially compensated?
Chair: Lizette Caballero (US)
Moderators: Paul Eldridge (US), Ann Wilson (US), Martin Hildebrandt (DE), Karen Snow (US), Lynn O’Donnell (US), Michael Boo (US), Lizette Caballero (US), Renee Smilee (US)

3:30pm – 5:00pm
WORKSHOP 1 Grand Ballroom A
ISCT/USP Joint Session: Ancillary materials
Co–Chairs: Elizabeth J. Read (US) and Fouad Atouf (US)
Speakers:
Elizabeth J. Read (US) – Ancillary Materials: Definitions, Regulatory Framework, and USP’s Risk–Tiered Approach
Nicole Provost (US) – Ancillary Materials in Cell Therapy Product Development
Felicia Rosenthal (DE) – Cytokines and Growth Factor for Ex vivo Cell Culture

WORKSHOP 2 Grand Ballroom B
Induced Cells for Neurological Disorders
Chair: Josef Priller (DE)
Speakers:
Josef Priller (DE) – Induced stem cells in research and therapy of neuropsychiatric disorders
Philip Horner (US) – Neural stem cells derived from human iPS improve forelimb recovery following spinal cord injury
Philip Schwartz (US) – An approach to immune-matched neurotherapy in pediatric neurodegenerative diseases

WORKSHOP 3 Grand Ballroom C
Expansion of Cord Blood
Chair: Colleen Delaney (US)
Speakers:
Elizabeth Csaszar (CA) – Harnessing hematopoietic stem cell self–renewal to enable therapies
Elizabeth J. Shpall (US) – Graft Engineering: The future of cord blood transplantation
Colleen Delaney (US) – Enhancing myeloid recovery after cord blood transplantation by infusion of cord blood stem/progenitor cells expanded in the presence of Notch ligand

3:15pm – 3:30pm Coffee Break with Exhibits Metropolitan Ballroom & Foyer, Ballard Room
SEATTLE 2012
18TH ANNUAL MEETING
www.celltherapy2012.com

WEDNESDAY JUNE 6, 2012

3:30pm – 5:00pm

STRATEGIES FOR COMMERCIALIZATION TRACK 3
Scalable Technologies for Phase 3 and Cell Therapy Commercial Products
Co-Chairs: Frida Grynspan (IL) and Steve Oh (SG)
Speakers:
Jaeseung Lim (KR) – The autologous T cell therapy product in Korea
Jef Pinxteren (BE) – Extensive quality control of MultiStem® cells isolated and expanded using the Quantum CES
Steve Oh (SG) – Stem cell bioprocessing: Superior cell expansion and differentiation on microcarriers
Lye Theng Lock (US) – Scalable kSep Process for Therapeutic Cell Concentration and Residual Clearance

TECHNICAL APPLICATIONS TRACK 3
Optimizing Clinical Outcomes of Cord Blood Transplantation through Enhanced Selection, Testing and Preparation
Chair: Donna Regan (US)
Speakers:
Joanne Kurtzberg (US) – How does cord blood potency impact clinical outcomes after cord blood transplantation?
Donna Wall (CA) – Preparation of cord blood for infusion: wash, no wash, or somewhere in between
Karen Ballen (US) – Optimal Cord Blood Unit Selection: Beyond Cell Dose

5:00pm – 6:00pm
POSTER SESSION 1
Ravenna Room

THURSDAY JUNE 7, 2012

7:00am – 4:00pm
Registration Open
Grand Ballroom Foyer

Corporate Tutorial Hosted by CellGenix GmbH and AFC (Refer to Corporate Guide for details)
Grand Ballroom A

7:30am – 8:30am

TECHNICAL SESSION 3
Cell Engineering
Chair: David DiGiusto (US)
Speakers:
David DiGiusto (US) – Zinc Finger Nuclease mediated genomic editing of CCR5 in human hematopoietic stem and progenitor cells for clinical application in HIV gene therapy
Christine Brown (US) – Phenotypic and Functional Attributes of Lentivirus Modified CD19–specific Human CD8+ Central Memory T Cells Manufactured at Clinical Scale

TECHNICAL SESSION 4
Funding for Early Stage Cell Based Therapies
Chair: Ellen Feigal (US)
Speakers:
Ellen Feigal (US) – Advancing Stem Cell Science Towards Therapies for Patients: CIRM’s Initiatives and Funding Opportunities
Lis Welniak (US) – NHLBI Update on Funding and Resources for Studies in Cellular Therapy

STRATEGIES FOR COMMERCIALIZATION TRACK 4
Cell Characterization Assays
Co-Chairs: Wouter Van’t Hof (US) and Timothy Fong (US)
Speakers:
Wouter Van’t Hof (US) – Potency assay development for MultiStem, a stromal cell therapy product
Amy Putnam (US) – Bench to Bedside: Successful Implementation of a Phase I Clinical Trial from an Academic Standpoint
TECHNICAL APPLICATIONS TRACK 4
Preparing Agreements for Contract Services Inside and Outside Your Institution
Chair: Ann Wilson (US)
Speakers: Victor Lemas (US) – Why you need to care about Internal Agreements?
Liz Cardwell (US) – Great Expectations: External Supplier Agreements

PLENARY SESSION 3 – STEM CELLS FOR GENE THERAPY
Chair: Hans-Peter Kiem (US)
Speakers:
Christoph Klein (DE) – Hematopoietic stem cell gene therapy for Wiskott–Aldrich Syndrome – efficacy and risks
Nathalie Cartier (FR) – Hematopoietic stem cell gene therapy for X-linked Adrenoleukodystrophy
Andrew Scharenberg (US) – Cell engineering with rare cleaving nucleases: technology landscape and applications
CME credit hours: 1.5

TECHNICAL APPLICATIONS TRACK 5
Translating Science from Bench to Bedside with Real Case Scenarios
Chair: Renee Smilee (US)
Speakers:
Ian Nicoud (US) – Part I: From model to manufacture – creating a clinical product from research findings
Jason Carstens (US) – Part 2: Process Development and Design for Manufacturing
Tory Lake (US) – Part 3: Navigating the regulatory path to clinical application
Colleen Delaney (US) – Part 4: Realizing the goal – clinical outcomes and future directions

ORAL ABSTRACT PRESENTATIONS 4
Basic Biology of Non–Hematopoietic Stem Cells/Non–Hematopoietic Stem Cells Towards Clinics
Chair: Luc Sensebé (FR)
HUMAN MESENCHYMAL STEM CELLS EXPRESS PROTEINS BELONGING TO OR RELATED TO THE IL1 FAMILY THAT CONTRIBUTE TO THEIR ANTI–INFLAMMATORY ACTIVITY (ABSTRACT #17)
Speaker: Siddaraju Boregowda (US)
REGULATING HUMAN MESENCHYMAL STEM CELLS FOR OSTEOGENIC TISSUE REPAIR BY P63 AND P38 ISOFORMS (ABSTRACT #18)
Speaker: Guy Howard (US)
MSC FUNCTIONALITY AND ROBUSTNESS OF THE MSC EXPANSION PROCESS ARE CRITICALLY DEPENDENT ON TISSUE SOURCE AND EXPANSION CONDITIONS (ABSTRACT #19)
Speaker: Helene Roelofs (NL)
MESENCHYMAL STROMAL CELL THERAPY FOR REFRACTORY CROHN’S DISEASE (ABSTRACT #20)
Speaker: Janice Fogarty (AU), Tech Travel Award Recipient
MOBILIZATION OF MESENCHYMAL STEM CELLS FROM THE BONE MARROW TO PERIPHERAL BLOOD (ABSTRACT #21)
Speaker: Ian McNiece (US)
PROSPECTIVELY ISOLATED SCAVENGING BONE–MARROW SINUSOIDAL ENDOTHELIAL CELLS HOME TO, AND REVASCULARIZE THE BONE MARROW OF TRANSPLANTED ABLATED RECIPIENTS (ABSTRACT #16)
Speaker: Susie Nilsson (AU)
10:45am – 12:15pm

**ORAL ABSTRACT PRESENTATIONS 5**

**Hematopoietic Stem Cells**

Co-Chairs: Susie Nilsson (AU) and Shelly Heimfeld (US)

**OPTIMIZING MEGAKARYOCYTE POLYPLOIDIZATION INCREASES PLATELET RELEASE IN CULTURE (ABSTRACT #22)**
Speaker: Mauro Avanzi (US)

**HEMATOPOIETIC STEM CELLS AND MEGAKARYOCYTE PROGENITORS AND THEIR SUBSETS DIFFER IN NORMAL AND MEYELOPROLIFERATIVE DISEASE STATES (ABSTRACT #23)**
Speaker: Varda Deutsch (IL)

**ALDH6 CONTENT OF SEGMENTS FROM BANKED CORD BLOODS PREDICTS ENGRAFTMENT AFTER CORD BLOOD TRANSPLANTATION (ABSTRACT #24)**
Speaker: Kevin Shoulars (US)

**NANOLITER DROPLET VITRIFICATION FOR BLOOD AND STEM CELL CRYOPRESERVATION (ABSTRACT #25)**
Speaker: Claudia Zylberberg (US)

**LUMINOMETRIC DETERMINATION OF PROGENITOR CELL FUNCTION IN CRYOPRESERVED PERIPHERAL BLOOD STEM CELL HARVESTS (ABSTRACT #26)**
Speaker: Beate Wagner (DE)

**WHAT CLINICAL CHARACTERISTICS OF AFRICAN AMERICAN MOTHERS AND BABIES FAVORABLY INFLUENCE CORD BLOOD POTENCY? DEFINING PARAMETERS THAT CAN GUIDE PUBLIC CORD BLOOD COLLECTION (ABSTRACT #27)**
Speaker: Kristin Page (US)

---

**STRATEGIES FOR COMMERCIALIZATION TRACK 5**

Key Considerations for Cell Therapy Pivotal Trials and Beyond
Chair: Darin Weber (US)

Speakers:
Lynn Allen–Hoffmann (US) – *Great Expectations: Readying your Technology for Regulatory Assessment*
Paul Williamson (US) – *Development of Cell–based Therapies in a Large Organization: Orchestrate for Success*
Darin Weber (US) – *Insights and Considerations in Preparing for Phase 3 Cell Therapy Studies*

---

**TECHNICAL APPLICATIONS TRACK 6**

Regulations Around the World
Chair: Karen Edward (US)

Speakers:
Martin Bleasdale (AU) – *Regulations around the world – an Australian perspective*
Mark Lowdell (UK) – *Regulation of ATMP trials in the EU: is it breaking the ‘virtuous circle’?*
Halvard Bönig (DE) – *Academia and advanced cell therapy: A German Perspective*
Jaeseung Lim (KR) – *The regulation and the development of cell therapy products in Korea*

---

12:15pm – 1:45pm Lunch with Exhibits

**Metropolitan Ballroom & Foyer, Ballard Room**

**Corporate Tutorial Hosted by ATMI LifeSciences** *(Refer to Corporate Guide for details)*
Grand Ballroom A

**Corporate Tutorial Hosted by Charter Medical** *(Refer to Corporate Guide for details)*
Grand Ballroom B

**Corporate Tutorial Hosted by Panasonic Healthcare Company of North America** *(Refer to Corporate Guide for details)*
Grand Ballroom C

**Corporate Tutorial Hosted by STEMCELL Technologies** *(Refer to Corporate Guide for details)*
Grand Ballroom D
1:45pm – 3:15pm

PLENARY SESSION 4 – REGENERATIVE MEDICINE AND POSITIONING FOR COMMERCIAL SUCCESS

Co-Chairs: Kurt Gunter (US) and Tracey Lodie (US)

Speakers:
- John McMannis (US) – “Off the Shelf” Stem Cell Products for Regenerative Medicine
- Mark Frolich (US) – Commercialization of Sipuleucel-T, the First FDA Approved Autologous Cellular Immunotherapy for Cancer
- Gil Beyen (BE) – Lessons from the commercial roll out of ChondroCelect in Europe

Grand Ballroom ABC

3:15pm – 3:30pm Coffee Break with Exhibits

3:30pm – 5:00pm

WORKSHOP 4
ISCT Reimbursement Roundtable Highlights

Chair: Richard Maziarz (US)

Speakers:
- Robert Deans (US)
- Richard Maziarz (US)

Grand Ballroom A

3:30pm – 5:00pm

STRATEGIES FOR COMMERCIALIZATION TRACK 6
Sourcing Biologic Materials and Managing Supply Chains – Quality Considerations

Chair: Scott Burger (US)

Speakers:
- Dominic Clarke (US) – Managing Particulates in Cellular Therapy
- Gaytha McPherson (US) – Optimizing Apheresis Cellular Collections
- Emmanuelle Charton (Council of Europe) – How the European Pharmacopoeia can contribute to the quality of raw materials for the production of cellular and gene transfer products
- Hermann Bohnenkamp (DE) – Controlled, standardized cytokines and cell culture media for manufacturing Advanced Therapies

Grand Ballroom D

5:00pm – 6:00pm POSTER SESSION 2

Ravenna Room

5:00pm – 6:00pm

TECHNICAL APPLICATIONS TRACK 8
Challenges New Customers Present to the CT Lab

Chair: Lynn O’Donnell (US)

Speakers:
- Carolyn Lutzko (US) – The Art and Science of Translating a Cell Therapy from Mouse to Man
- Tom Leemhuis (US) – Teaching surgeons how to do cell therapy
- Deborah Griffin (US) – Practical methods for regulatory compliance and documentation of new protocol implementation for the CT Lab

Willow Room
### FRIDAY JUNE 8, 2012

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am – 3:00pm</td>
<td>Registration Open</td>
<td>Grand Ballroom Foyer</td>
</tr>
<tr>
<td>7:30am – 8:30am</td>
<td>TECHNICAL SESSION 5</td>
<td>Grand Ballroom B</td>
</tr>
<tr>
<td></td>
<td>Ex–vivo and in–vivo graft engineering</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: Stephan Mielke (DE)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speakers:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stephan Mielke (DE) – <strong>TH9402–based, ex vivo allodepletion to improve matched and mismatched transplants</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Catherine Bollard (US) – <strong>Ex vivo expanded multi–virus specific T cells to reduce infectious complications after allogeneic stem cell transplantation</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Paul O’Donnell (US) – <strong>Cyclophosphamide–Induced Tolerance in BMT</strong></td>
<td></td>
</tr>
<tr>
<td>7:30am – 8:30am</td>
<td>TECHNICAL SESSION 6</td>
<td>Grand Ballroom C</td>
</tr>
<tr>
<td></td>
<td>TPP Workshop</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: Ellen Feigal (US)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speakers:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ellen Feigal (US) – <strong>Target Product Profile – Key Guide in Product Development</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Wilson Bryan (US) – <strong>Target Product Profile – A Regulatory Perspective</strong></td>
<td></td>
</tr>
<tr>
<td>7:30am – 8:30am</td>
<td>TECHNICAL SESSION 7</td>
<td>Grand Ballroom A</td>
</tr>
<tr>
<td></td>
<td>Freezing of Living Cells for Cellular Therapy: A Challenge for Biomedical Scientists</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair and Speaker: Dayong Gao (US)</td>
<td></td>
</tr>
<tr>
<td>8:45am – 10:15am</td>
<td>PLENARY SESSION 5 – REGENERATION REVISITED</td>
<td>Grand Ballroom ABC</td>
</tr>
<tr>
<td></td>
<td>Chair: John Rasko (AU)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speakers:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Andras Nagy (CA) – <strong>Toward understanding the process of somatic cell reprogramming to pluripotency</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Shahin Rafii (US) – <strong>Vascular niche-derived angiocrine factors initiate and sustain organ regeneration</strong></td>
<td></td>
</tr>
<tr>
<td>8:45am – 10:15am</td>
<td>TECHNICAL APPLICATIONS TRACK 10</td>
<td>Willow Room</td>
</tr>
<tr>
<td></td>
<td>Lean Process for Processing Laboratories: When can we use it with examples</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: Karen Foster (US)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speakers:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Brent McKinnon (US) – <strong>ViaCord Cord Blood Processing – Matching Unit Cycle Time to Take Time</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jennifer Glejf (US) – <strong>Getting LEAN in the Human Cell Therapy Lab: How Applying LEAN Principles to One Area of the Lab Caught on Like Wildfire</strong></td>
<td></td>
</tr>
<tr>
<td>10:15am – 10:45am</td>
<td>Coffee Break with Exhibits</td>
<td>Metropolitan Ballroom &amp; Foyer, Ballard Room</td>
</tr>
</tbody>
</table>
10:45am – 11:45pm

ORAL ABSTRACT PRESENTATIONS 6
Lab Practices/Legal and Regulatory Affairs
Grand Ballroom A

Co-Chairs: Deborah Lamontagne (US) and Karen Nichols (US)

POST THAW CD34 RECOVERY AND VIABILITY OF HEMATOPOIETIC PROGENITOR CELLS IS A VALUABLE CLINICAL TOOL IN AUTOLOGOUS BLOOD AND MARROW TRANSPLANTS (ABSTRACT #29)
Speaker: Susan Berrigan (CA)

STABILITY OF THAWED HEMATOPOIETIC PROGENITOR CELLS (HPC) IN DIMETHYL SULFOXIDE (DMSO) IN FILTERED AND UNFILTERED PRODUCTS (ABSTRACT #28)
Speaker: Mehraboon Irani (US)

ESTABLISHING THE NECESSARY DATA TO MODEL THE FUTURE RESOURCE REQUIREMENTS AND PREDICTED HEALTHCARE TARGETS FOR CELL THERAPY AS PART OF ROUTINE CLINICAL PRACTICE (ABSTRACT #30)
Speaker: Emily Culme-Seymour (UK)

REGULATORY IMPLICATIONS OF ALLOGENEIC CELL BANKING STRATEGY (ABSTRACT #31)
Speaker: Christopher Bravery (UK)

11:45pm – 1:15pm Lunch with Exhibits

12:00pm – 1:00pm ANNUAL GENERAL MEETING (AGM)
All ISCT Members invited to attend

1:15pm – 2:45pm WORKSHOP 6
ISCT/PACT Joint Session: PACT II: Scope of Projects at Pre-Clinical and Manufacturing Stages of Development
Grand Ballroom A

Co-Chairs: Shelly Heimfeld (US) and Les Silberstein (US)

Speakers:
Les Silberstein (US) – Objectives of the PACT program
Myriam Armant (US) – Examples of PACT II Enabled Translational and Clinical Applications at CHCT
David McKenna (US) – Challenges in Moving Cell Therapies to the Clinical Arena: The Minnesota PACT Experience
Adrian Gee (US) – PACT-Supported Development of Virus-Directed T Cell Therapy
Larry Couture (US) – Process development for scalable cardiomyocyte differentiation from hES cells

1:15pm – 2:45pm WORKSHOP 6
ISCT/PACT Joint Session: PACT II: Scope of Projects at Pre-Clinical and Manufacturing Stages of Development
Grand Ballroom A

Co-Chairs: Shelly Heimfeld (US) and Les Silberstein (US)

Speakers:
Les Silberstein (US) – Objectives of the PACT program
Myriam Armant (US) – Examples of PACT II Enabled Translational and Clinical Applications at CHCT
David McKenna (US) – Challenges in Moving Cell Therapies to the Clinical Arena: The Minnesota PACT Experience
Adrian Gee (US) – PACT-Supported Development of Virus-Directed T Cell Therapy
Larry Couture (US) – Process development for scalable cardiomyocyte differentiation from hES cells

1:15pm – 2:45pm WORKSHOP 6
ISCT/PACT Joint Session: PACT II: Scope of Projects at Pre-Clinical and Manufacturing Stages of Development
Grand Ballroom A

Co-Chairs: Shelly Heimfeld (US) and Les Silberstein (US)

Speakers:
Les Silberstein (US) – Objectives of the PACT program
Myriam Armant (US) – Examples of PACT II Enabled Translational and Clinical Applications at CHCT
David McKenna (US) – Challenges in Moving Cell Therapies to the Clinical Arena: The Minnesota PACT Experience
Adrian Gee (US) – PACT-Supported Development of Virus-Directed T Cell Therapy
Larry Couture (US) – Process development for scalable cardiomyocyte differentiation from hES cells

1:15pm – 2:45pm WORKSHOP 6
ISCT/PACT Joint Session: PACT II: Scope of Projects at Pre-Clinical and Manufacturing Stages of Development
Grand Ballroom A

Co-Chairs: Shelly Heimfeld (US) and Les Silberstein (US)

Speakers:
Les Silberstein (US) – Objectives of the PACT program
Myriam Armant (US) – Examples of PACT II Enabled Translational and Clinical Applications at CHCT
David McKenna (US) – Challenges in Moving Cell Therapies to the Clinical Arena: The Minnesota PACT Experience
Adrian Gee (US) – PACT-Supported Development of Virus-Directed T Cell Therapy
Larry Couture (US) – Process development for scalable cardiomyocyte differentiation from hES cells

1:15pm – 2:45pm WORKSHOP 6
ISCT/PACT Joint Session: PACT II: Scope of Projects at Pre-Clinical and Manufacturing Stages of Development
Grand Ballroom A

Co-Chairs: Shelly Heimfeld (US) and Les Silberstein (US)

Speakers:
Les Silberstein (US) – Objectives of the PACT program
Myriam Armant (US) – Examples of PACT II Enabled Translational and Clinical Applications at CHCT
David McKenna (US) – Challenges in Moving Cell Therapies to the Clinical Arena: The Minnesota PACT Experience
Adrian Gee (US) – PACT-Supported Development of Virus-Directed T Cell Therapy
Larry Couture (US) – Process development for scalable cardiomyocyte differentiation from hES cells

1:15pm – 2:45pm WORKSHOP 6
ISCT/PACT Joint Session: PACT II: Scope of Projects at Pre-Clinical and Manufacturing Stages of Development
Grand Ballroom A

Co-Chairs: Shelly Heimfeld (US) and Les Silberstein (US)

Speakers:
Les Silberstein (US) – Objectives of the PACT program
Myriam Armant (US) – Examples of PACT II Enabled Translational and Clinical Applications at CHCT
David McKenna (US) – Challenges in Moving Cell Therapies to the Clinical Arena: The Minnesota PACT Experience
Adrian Gee (US) – PACT-Supported Development of Virus-Directed T Cell Therapy
Larry Couture (US) – Process development for scalable cardiomyocyte differentiation from hES cells
FRIDAY JUNE 8, 2012

WORKSHOP 7
MSC Production and Clinical Uses: Impact of Production Methods on Potency and Safety
Co-Chairs: Luc Sensebé (FR) and Mauro Krampera (IT)
Speakers:
Hillard Lazarus (US) – Novel uses for MSCs and MAPCs
David Stroncek (US) – BM MSCs Production and Assessment for Clinical Applications
Luc Sensebé (FR) – MSCs from Safety Concerns to Controls

STRATEGIES FOR COMMERCIALIZATION TRACK 8
Tissue Engineering in 2012: Lost in Commercial Translation?
Chair: Sharon Presnell (US)
Speakers:
Sharon Presnell (US) – Capturing the value from science: Translating promising research into a tangible asset
Dean Tozer (US) – Ushering an innovative regenerative medicine product from development to the market
Timothy Fong (US) – From Idea to Product: The pathway from academic innovation to a commercial manufacturing process

TECHNICAL APPLICATIONS TRACK 12
Strenuous Standards: Savvy Solutions
Chair: Lynn O’Donnell (US)
Speakers:
Douglas Padley (US) – The Search for Balance: Control vs Creativity in the Development and Implementation of Novel Cellular Therapy Product Trials
Jessica Carmen (US) – Molecular Trilineage Assay for Identity Testing of hMSCs
John Duguid (US) – Validation of Rapid Mycoplasma Testing using Real–Time PCR
Michele Cottler–Fox (US) – Garbage in, garbage out: a predictive formula to improve efficiency and quality for HPC collection and processing facilities

2:45pm – 2:50pm Break

2:50pm – 2:55pm ANNOUNCEMENT: BEST POSTER AWARD/BEST ORAL ABSTRACT AWARD RECIPIENTS

PLENARY SESSION 6 – IMMUNOTHERAPY AND T–CELLS
Chair: Philip Greenberg (US)
Speakers:
Philip Greenberg (US) – T cells vs. tumors: Preparing T cells for the kill
Michael Jensen (US) – Enhancing the IQ of CAR–modified T Cells
Renier Brentjens (US) – Chimeric antigen receptor (CAR) modified T cells as a novel approach to immuno–therapy of B cell malignancies

TECHNICAL APPLICATIONS TRACK 13
ISBT Labeling Implementation – Presentation of Real Scenarios
Co-Chairs: Lizette Caballero (US) and Leigh Sims Poston (US)
Speakers:
Kathy Watkins (US) – ISBT Labeling: One Small Lab’s Implementation Experience
Mary McLeod (US) – Developing an ISBT 128 plan for Cell Therapy Labs and Apheresis Collection Facilities